Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop, Am J Ophthalmol, vol.140, issue.3, pp.509-525, 2005. ,
Cystoid Macular Edema in Uveitis, Dev Ophthalmol, vol.47, pp.136-183, 2010. ,
DOI : 10.1159/000320077
Epidemiology of Uveitis, International Ophthalmology Clinics, vol.45, issue.2, pp.1-13, 2005. ,
DOI : 10.1097/01.iio.0000155938.83083.94
S antigen-induced experimental autoimmune uveo-retinitis in rats, Current Eye Research, vol.101, issue.6, pp.327-364, 1981. ,
DOI : 10.3109/02713688108998359
An endotoxininduced serum factor that causes necrosis of tumors, Proc Natl Acad Sci, 1975. ,
The role of tumor necrosis factor-alpha in the induction of experimental autoimmune uveoretinitis in mice, Invest Ophthalmol Vis Sci, vol.35, issue.11, pp.3884-3893, 1994. ,
Quantitative assessment of the integrity of the blood-retinal barrier in mice, Invest Ophthalmol Vis Sci, vol.43, issue.7, pp.2462-2469, 2002. ,
Aqueous Humor and Serum Tumor Necrosis Factor-?? in Clinical Uveitis, Ophthalmic Research, vol.33, issue.5, pp.251-256, 2001. ,
DOI : 10.1159/000055677
Neutralizing Tumor Necrosis Factor-?? Activity Suppresses Activation of Infiltrating Macrophages in Experimental Autoimmune Uveoretinitis, Investigative Opthalmology & Visual Science, vol.44, issue.7, pp.3034-3075, 2003. ,
DOI : 10.1167/iovs.02-1156
Sequential induction of angiogenic growth factors by TNF-?? in choroidal endothelial cells, Journal of Neuroimmunology, vol.171, issue.1-2, pp.45-56, 2006. ,
DOI : 10.1016/j.jneuroim.2005.09.018
Golimumab as rescue therapy for refractory immune-mediated uveitis: a three-center experience Golimumab for the treatment of refractory juvenile idiopathic arthritis-associated uveitis, Mediators Inflamm. J Ophthalmic Inflamm Infect, vol.2014, pp.717598-717614, 2012. ,
Long-term treatment with golimumab for severe uveitis Treatment of seronegative spondyloarthropathy-associated uveitis with golimumab: retrospective case series, Ocul Immunol Inflamm. 2014 Clin Experiment Ophthalmol, vol.2242, issue.24, pp.90-95, 2014. ,
Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease Arthritis Rheum Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation, Ophthalmology, vol.45, issue.3, pp.252-259, 2001. ,
Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and Malignancies, JAMA, vol.295, issue.19, pp.2275-85, 2006. ,
DOI : 10.1001/jama.295.19.2275
Safety of anti-TNF-?? therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis, Rheumatology, vol.45, issue.10, pp.1294-1301, 2006. ,
DOI : 10.1093/rheumatology/kel123
Use of infliximab to treat psoriatic arthritis in HIV-positive patients, Joint Bone Spine, vol.74, issue.2, 2007. ,
DOI : 10.1016/j.jbspin.2006.05.012
TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists, International Journal of Dermatology, vol.22, issue.5, pp.619-644, 2011. ,
DOI : 10.1111/j.1365-4632.2011.04871.x
Demyelination during anti-TNF?? therapy for ankylosing spondylitis, Modern Rheumatology, vol.70, issue.1, pp.303-310 ,
DOI : 10.1001/archneurol.2009.11
Malignancies and anti-TNF therapy in rheumatoid arthritis: a single-center observational cohort study, Backhouse OC. Does etanercept induce uveitis, 2003. ,
DOI : 10.1007/s10067-015-3026-7
Anti-TNF Therapy Against Congestive Heart Failure Investigators. Randomized, double-blind, placebocontrolled , pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factoralpha , in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders A pilot study of normative data for macular thickness and volume measurements using cirrus high-definition optical coherence tomography, Ophthalmology. Retina, vol.8710712131, issue.3139, pp.9253133-40785, 2003. ,
Recommendations for using TNF?? antagonists and French Clinical Practice Guidelines endorsed by the French National Authority for Health, Joint Bone Spine, vol.80, issue.6, 2013. ,
DOI : 10.1016/j.jbspin.2013.09.001
Infliximab and Adalimumab for Uveitis, Ocular Immunology and Inflammation, vol.18, issue.6, pp.18-26, 2012. ,
DOI : 10.1136/bmj.b2480
A Prospective Trial of Infliximab Therapy for Refractory Uveitis, Archives of Ophthalmology, vol.123, issue.7, pp.903-915, 2005. ,
DOI : 10.1001/archopht.123.7.903
Infliximab in the treatment of refractory ocular inflammatory diseases 2015 Feb Treatment of refractory posterior uveitis with infliximab: a 7-year follow-up study Infliximab for the treatment of refractory noninfectious Uveitis: a study of 88 patients with long-term follow-up, Asia Pac J Ophthalmol (Phila) Scand J Rheumatol. Feb Kruh JN, vol.438, issue.38, pp.19-2458, 2009. ,
Treatment of Refractory Uveitis with Adalimumab: A Prospective Multicenter Study of 131 Patients, Ophthalmology, vol.119, issue.8, pp.1575-81, 2012. ,
DOI : 10.1016/j.ophtha.2012.02.018
A three-centre experience with adalimumab for the treatment of non-infectious uveitis, British Journal of Ophthalmology, vol.97, issue.2, pp.134-142, 2013. ,
DOI : 10.1136/bjophthalmol-2011-301401
Anti-TNF agents for Behçet's disease: analysis of published data on 369 patients. Semin Arthritis Rheum Longterm efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study, Rheumatology, vol.4146, issue.17, pp.61-70, 2007. ,
Efficacy of infliximab in refractory Behçet's disease-associated and idiopathic posterior segment uveitis: a prospective, follow-up study of 50 patients, Biologics, vol.6, pp.5-12, 2012. ,
Infliximab Treatment of Patients with Birdshot Retinochoroidopathy, Ophthalmology, vol.120, issue.3, p.2013 ,
DOI : 10.1016/j.ophtha.2012.05.048
Anti-TNF-? therapy in refractory uveitis associated with sarcoidosis: Multicenter study of 17 patients Anti-TNF-alpha therapy for sight threatening uveitis, Semin Arthritis Rheum Br J Ophthalmol, vol.4889, issue.5, pp.533-539, 2005. ,
Anti-TNF-? agents for refractory cystoid macular edema associated with noninfectious uveitis, Graefes Arch Clin Exp Ophthalmol. 2014, vol.138252, issue.504, pp.648-50633, 2004. ,
Infliximab Therapy for the Treatment of Refractory Ocular Inflammatory Disease, Archives of Ophthalmology, vol.125, issue.7, pp.895-900, 2007. ,
DOI : 10.1001/archopht.125.7.895
Anti-TNF-?? therapy for sight threatening uveitis, British Journal of Ophthalmology, vol.89, issue.5, pp.533-539, 2005. ,
DOI : 10.1136/bjo.2003.037192
Resolution of refractory uveitis, switching anti-TNF treatment. Reumatol Clin, pp.379-80, 2012. ,
Switching biologic agents for uveitis, Eye, vol.31, issue.9 ,
DOI : 10.1038/eye.2009.203
Treatment of early rheumatoid arthritis: A randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone, Arthritis & Rheumatism, vol.41, issue.12, pp.3919-3946, 2007. ,
DOI : 10.1002/art.23055
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease, New England Journal of Medicine, vol.362, issue.15, pp.1383-95, 2010. ,
DOI : 10.1056/NEJMoa0904492
Infliximab therapy for refractory uveitis: 2-year results of a prospective trial, Arch Ophthalmol, 2009. ,
A threecentre experience with adalimumab for the treatment of non-infectious uveitis, Br J Ophthalmol. 2013 Feb, vol.197, issue.2, pp.134-142 ,
Ocular manifestations of multiple sclerosis, Current Opinion in Ophthalmology, vol.16, issue.5, pp.315-335, 2005. ,
DOI : 10.1097/01.icu.0000179804.49842.e2
Long-term Risk of Malignancy Among Patients Treated With Immunosuppressive Agents for Ocular Inflammation: A Critical Assessment of the Evidence, e1. 62. Cordero-Coma M, Sobrin L. Anti-Tumor Necrosis Factor-? Therapy in Uveitis, pp.802-812, 2008. ,
DOI : 10.1016/j.ajo.2008.04.035
A Review of CT-P13: An Infliximab Biosimilar, BioDrugs, vol.10, issue.4, p.2014 ,
DOI : 10.1007/s40259-014-0094-1
Tocilizumab in uveitis refractory to other biologic drugs: a study of 3 cases and a literature review, Clin Exp Rheumatol, vol.32, issue.4, pp.54-57, 2014. ,
Non-anti-TNF biologic modifier drugs in non-infectious refractory chronic uveitis: The current evidence from a systematic review Relationship between serum infliximab levels and acute uveitis attacks in patients with Behcet disease, Semin Arthritis Rheum Br J Ophthalmol, vol.6695, issue.4, pp.549-52, 2011. ,
Long-Term Effects of Intravitreal Infliximab for Treatment of Sight Threatening Chronic Noninfectious Uveitis, Journal of Ocular Pharmacology and Therapeutics, 2012. ,
DOI : 10.1089/jop.2011.0199
Intravitreal Infliximab for Sight-Threatening Relapsing Uveitis in Beh??et Disease: A Pilot Study in 15 Patients, American Journal of Ophthalmology, vol.154, issue.3, pp.534-541 ,
DOI : 10.1016/j.ajo.2012.03.035
Intravitreal Adalimumab in Active Noninfectious Uveitis: A Pilot Study, Ocul Immunol Inflamm, pp.1-8, 2015. ,
Les patients non répondeurs ou ayant présenté une récidive inflammatoire dans les 3 premiers mois étaient donc tous traités par Adalimumab En tenant compte de l'étiologie, étaient contrôlés 100,0% des patients atteints d'une maladie de Behçet (N=7), 100% des patients atteints d'une maladie de Birdshot (N=3), 100% des patients atteints d'une sarcoïdose (N=2), et 55, 5% des patients atteints d'uvéites idiopathiques et autres (N=5) (figures 3 ,
Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel, American Journal of Ophthalmology, vol.131, issue.5, p.679, 2001. ,
DOI : 10.1016/S0002-9394(01)00830-3
An endotoxininduced serum factor that causes necrosis of tumors, Proc Natl Acad Sci, 1975. ,
The role of tumor necrosis factor-alpha in the induction of experimental autoimmune uveoretinitis in mice, Invest Ophthalmol Vis Sci, vol.35, issue.11, pp.3884-3893, 1994. ,
Aqueous Humor and Serum Tumor Necrosis Factor-?? in Clinical Uveitis, Ophthalmic Research, vol.33, issue.5, pp.251-256, 2001. ,
DOI : 10.1159/000055677
Neutralizing Tumor Necrosis Factor-?? Activity Suppresses Activation of Infiltrating Macrophages in Experimental Autoimmune Uveoretinitis, Investigative Opthalmology & Visual Science, vol.44, issue.7, pp.3034-3075, 2003. ,
DOI : 10.1167/iovs.02-1156
Tumor necrosis factor ?? blockade with infliximab for refractory uveitis and scleritis, Ophthalmology, vol.111, issue.2, pp.352-358, 2004. ,
DOI : 10.1016/S0161-6420(03)00721-8
Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop, Am J Ophthalmol, vol.140, issue.3, pp.509-525, 2005. ,
Infliximab and Adalimumab for Uveitis, Ocular Immunology and Inflammation, vol.18, issue.6, pp.18-26, 2012. ,
DOI : 10.1136/bmj.b2480
Infliximab in the Treatment of Refractory Ocular Inflammatory Diseases, Asia-Pacific Journal of Ophthalmology, vol.4, issue.1, pp.19-24, 2014. ,
DOI : 10.1097/APO.0000000000000036
Treatment of refractory posterior uveitis with infliximab: a 7???year follow???up study, Scandinavian Journal of Rheumatology, vol.46, issue.1, pp.58-62, 2009. ,
DOI : 10.1001/archopht.123.7.903
Infliximab and adalimumab for uveitis Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients, Ocul Immunol Inflamm. 2012 Feb; Ophthalmology, vol.20119, issue.148, pp.18-261575, 2012. ,
A three-centre experience with adalimumab for the treatment of non-infectious uveitis, British Journal of Ophthalmology, vol.97, issue.2, pp.134-142, 2013. ,
DOI : 10.1136/bjophthalmol-2011-301401
The Effect of Anti-Tumour Necrosis Factor alpha (Infliximab) on Sight-Threatening Uveitis in a Patient with Beh??et???s Disease, Adv Exp Med Biol, vol.528, pp.557-566, 2003. ,
DOI : 10.1007/0-306-48382-3_112
Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study, Rheumatology, vol.46, issue.7, pp.1161-1165, 2007. ,
DOI : 10.1093/rheumatology/kem101
Efficacy of infliximab in refractory Behçet's disease-associated and idiopathic posterior segment uveitis: a prospective, follow-up study of 50 patients, Biologics. Perra D, vol.6, issue.20, pp.5-12, 2012. ,
Adalimumab for the treatment of Behçet's disease: experience in 19 patients Rheumatology (Oxford), pp.1825-1856, 2012. ,
Evaluation of the Long-Term Efficacy and Safety of Infliximab Treatment for Uveitis in Beh??et's Disease, Ophthalmology, vol.121, issue.10, pp.1877-84, 2014. ,
DOI : 10.1016/j.ophtha.2014.04.042
Ocular Behçet's Disease Research Group Of Japan. Multicenter study of infliximab for refractory uveoretinitis in Behçet disease, Arch Ophthalmol. 2012, vol.130, issue.5, pp.592-600 ,
Adalimumab for treatment of severe Behçet's uveitis: a retrospective long-term follow-up study, Clin Exp Rheumatol, 2014. ,
Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders Infliximab treatment of patients with birdshot retinochoroidopathy, Rheumatology. Ophthalmology. Artornsombudh P Ophthalmology, vol.46121, issue.263, pp.736-41785, 2007. ,
Birdshot uveitis: current and emerging treatment options, Clin Ophthalmol, vol.8, pp.73-81, 2014. ,
Anti-TNF-? therapy in refractory uveitis associated with sarcoidosis: Multicenter study of 17 patients Anti-TNF-alpha therapy for sight threatening uveitis, Semin Arthritis Rheum Br J Ophthalmol, vol.3089, issue.5, pp.533-539, 2005. ,
Sequential induction of angiogenic growth factors by TNF-?? in choroidal endothelial cells, Journal of Neuroimmunology, vol.171, issue.1-2, pp.45-56, 2006. ,
DOI : 10.1016/j.jneuroim.2005.09.018
Anti-TNF-? agents for refractory cystoid macular edema associated with noninfectious uveitis, Graefes Arch Clin Exp Ophthalmol. 2014, vol.138252, issue.334, pp.648-50633, 2004. ,
Treatment of early rheumatoid arthritis: A randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone, Arthritis & Rheumatism, vol.41, issue.12, pp.3919-3946, 2007. ,
DOI : 10.1002/art.23055
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease, New England Journal of Medicine, vol.362, issue.15, pp.1383-95, 2010. ,
DOI : 10.1056/NEJMoa0904492
Switching biologic agents for uveitis, Eye, vol.31, issue.9 ,
DOI : 10.1038/eye.2009.203
Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and Malignancies, JAMA, vol.295, issue.19, pp.2275-85, 2006. ,
DOI : 10.1001/jama.295.19.2275
Safety of anti-TNF-?? therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis, Rheumatology, vol.45, issue.10, pp.1294-1301, 2006. ,
DOI : 10.1093/rheumatology/kel123
Demyelination during anti-TNF?? therapy for ankylosing spondylitis, Modern Rheumatology, vol.70, issue.1, pp.303-310 ,
DOI : 10.1001/archneurol.2009.11
Malignancies and anti-TNF therapy in rheumatoid arthritis: a single-center observational cohort study A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes, Clin Rheumatol Arch Ophthalmol, vol.41123, issue.7, pp.903-915, 2005. ,
Infliximab therapy for refractory uveitis: 2-year results of a prospective trial, Arch Ophthalmol, 2009. ,
Ocular manifestations of multiple sclerosis, Current Opinion in Ophthalmology, vol.16, issue.5, pp.315-335, 2005. ,
DOI : 10.1097/01.icu.0000179804.49842.e2
Anti???tumor necrosis factor-?? therapy in uveitis, Survey of Ophthalmology, vol.60, issue.6, 2015. ,
DOI : 10.1016/j.survophthal.2015.06.004